Macter International Ltd has emerged from the latest results season with a clear message for investors: momentum is back in branded generics, new biologics are scaling, and a bet on consumer beauty is moving from trial to traction. Management says the company is growing faster than the market, based on data from the healthcare data company IQVIA, aided by policy tailwinds from the deregulation of non essential drug prices and supported by a pipeline that now includes semaglutide in multiple delivery formats and a pending application for tirzepatide.
Macter closed FY25 with net sales of Rs9.9 billion, up 32% year on year from Rs7.5 billion in FY24, as mix shifted towards higher margin prescription brands and recently launched products. Gross margin widened from 42% to 45%, lifting gross profit 40% to Rs4.5 billion. Operating profit increased 76% to Rs1.2 billion, reflecting both the gross margin recovery and operating leverage, while profit after tax rose 73% to Rs738 million. The content in this publication is expensive to produce. But unlike other journalistic outfits, business publications have to cover the very organizations that directly give them advertisements. Hence, this large source of revenue, which is the lifeblood of other media houses, is severely compromised on account of Profit’s no-compromise policy when it comes to our reporting. No wonder, Profit has lost multiple ad deals, worth tens of millions of rupees, due to stories that held big businesses to account. Hence, for our work to continue unfettered, it must be supported by discerning readers who know the value of quality business journalism, not just for the economy but for the society as a whole.To read the full article, subscribe and support independent business journalism in Pakistan
